Status: Available
An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)
This Expanded Access Program provides investigational access to leronlimab (PRO 140) for patients with advanced or metastatic triple-negative breast cancer (TNBC) who lack satisfactory treatment options and are unable to participate in a clinical trial.
Trial details
Age: 18+Biological sex: AllType: Expanded AccessSponsor: CytoDyn, Inc.Updated: Apr 27, 2026Locations: 1
Eligibility criteria
Adult participants > 18 years of age. [+9]
Participants who have a history of allergic reactions attributed to compounds of... [+6]